ResMed, Inspire Medical Drop After Lilly’s Zepbound Study by Mark Eisenberg 24.06.2024 "ResMed and Inspire Medical stocks plummet after Eli Lilly's Zepbound trial success; Citi downgrades RMD, sees market shift. Read more ...
Lilly’s Zepbound Resolves Sleep Apnea in 52% of Patients by Mark Eisenberg 22.06.2024 Eli Lilly's Zepbound reduces sleep apnea by up to 52% in trials, showing promise beyond weight loss. FDA approval for ...
Pfizer’s Debt Concerns Cast Doubt on Viking Therapeutics Acquisition by Mark Eisenberg 01.04.2024 Pfizer's interest in the weight loss market is uncertain due to its significant debt of over $70 billion and recent ...
Wall Street Analyzes Eli Lilly’s Promising Outlook by Terry Bingman 22.01.2024 Discover the promising future for investors in Eli Lilly and Company (NYSE: LLY), a leader in the biopharmaceutical industry, with ...